EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

First-line Treatment Selection for Advanced Hepatocellular Carcinoma

Zainab Al Maqrashi, Brandon M. Meyers

Canadian Oncology Today · 2024

DOI: 10.58931/cot.2024.1325 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Oncology Today, 2024. Verfasst von Zainab Al Maqrashi und 1 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment landscape of advanced/unresectable hepatocellular carcinoma (uHCC) has rapidly evolved since 2018. Over recent years, various systemic therapies and treatment approaches have been explored. Systemic therapy has primarily relied on tyrosine kinase inhibitors (TKIs); however, immune checkpoint inhibitors (ICIs) have more recently entered the realm of the treatment armamentarium.

Zitieren

APA

Maqrashi, Z. A., & Meyers, B. M. (2024). First-line Treatment Selection for Advanced Hepatocellular Carcinoma. Canadian Oncology Today. https://doi.org/10.58931/cot.2024.1325

Vancouver

Maqrashi ZA, Meyers BM. First-line Treatment Selection for Advanced Hepatocellular Carcinoma. Canadian Oncology Today. 2024. doi:10.58931/cot.2024.1325

BibTeX
@article{Maqrashi2024,
  author = {Maqrashi, Zainab Al and Meyers, Brandon M.},
  title = {First-line Treatment Selection for Advanced Hepatocellular Carcinoma},
  journal = {Canadian Oncology Today},
  year = {2024},
  doi = {10.58931/cot.2024.1325}
}
Kostenlos starten →